To assess connections between sleeping quality and hearing impairment due to prolonged exposure to industrial noise. Observational cross-sectional study. Occupational clinic of the Clalit Health Services in Israel. 298 male volunteers occupationally exposed to harmful noise, who had an audiometric examination performed by an occupational nurse as a part of the national workers health supervision programs. The participants underwent an audiometric testing, and their sleep quality was measured by a validated Mini Sleep Questionnaire (MSQ). Participants with hearing loss greater than 25 dBA in the range of 1000–4000 Hz were defined as the research group (n = 99) and were compared to those with no hearing impairment (n = 199). Sleeping disorders were age related (30% higher MSQ score among workers above 50 years, P = 0.003). Tinnitus was the highest sleep disturbing factor, with 75% higher score among those affected, P = 0.001. In multiple linear regression analysis, tinnitus was the leading sleep-disturbing factor (regression coefficient B = 8.66, P < 0.001) followed by hearing impairment (regression coefficient B = 2.42, P = 0.084), adjusted for age (or years of exposure) and coffee drinking. A part of the MSQ, related to insomnia, was further evaluated using logistic regression models. Tinnitus was again the leading sleep disturbing factor [OR = 11.91; CI95% (1.56-91.2)], followed by hearing impairment [OR = 3.051; CI95% (1.18–7.86)]. Although tinnitus was the main sleep disrupting factor, hearing impairment among workers occupationally exposed to harmful noise, independently contributed to sleep impairment, especially to insomnia, regardless of age and years of exposure.
Background: Metabolic syndrome (MetS) comprises a cluster of metabolic abnormalities that increase the risk of type 2 diabetes mellitus (T2DM) and cardiometabolic morbidity. Although widely recognized, evidence on its documentation and follow-up in primary care is limited. This study aimed to evaluate the extent of MetS documentation in electronic medical records (EMRs), examine follow-up patterns and metabolic changes over time, and assess the incidence and predictors of new-onset T2DM according to baseline MetS severity. Methods: A retrospective cohort study was conducted on 8170 adults aged 30–50 years, insured by Clalit Health Services in Southern Israel, who met ATP III criteria for MetS in 2008 and were followed through 2015. MetS severity was classified as mild (three components), moderate (four), or severe (five). Changes in metabolic indices were assessed longitudinally, and predictors of T2DM were analyzed using Kaplan–Meier survival and multivariable Cox regression models. Results: Although all participants met the diagnostic criteria, only 1.6% had a recorded MetS diagnosis. Over the eight years of follow-up, 26% developed T2DM, with incidence increasing from 21% among those with mild MetS to 49% among those with severe MetS (p < 0.0001). Fasting plasma glucose rose significantly (median +13 mg/dL, p < 0.001), BMI remained stable, and modest improvements were observed in blood pressure and lipid levels. Elevated fasting glucose (HR 2.13, p < 0.001), higher BMI (HR 1.33, p = 0.010), and lower HDL (HR 1.26, p = 0.045) independently predicted diabetes onset. Conclusions: MetS remains markedly under-documented and insufficiently integrated into primary care follow-up. Despite regular clinical follow-up, improvements in metabolic indices were limited. These findings highlight the need for structured strategies to enhance MetS recognition and long-term management within routine practice.